Ask about this productRelated genes to: SPARCL1 antibody
- Gene:
- SPARCL1 NIH gene
- Name:
- SPARC like 1
- Previous symbol:
- -
- Synonyms:
- MAST9
- Chromosome:
- 4q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-09-17
- Date modifiied:
- 2016-10-05
Related products to: SPARCL1 antibody
Related articles to: SPARCL1 antibody
- The clinical relevance of mitochondrial RNA modification (MRM) in colorectal cancer (CRC), particularly its value for prognostic stratification, has not been fully defined. We integrated bulk transcriptomic profiles, machine learning-based model screening, single-cell analysis, and experimental validation to identify MRM score-associated prognostic genes and construct a CRC risk model. Seven CRC-related prognostic genes were selected: SPARCL1, MGP, PRELP, PALMD, TNS1, ARHGEF25, and PTGIS. These genes were incorporated into a risk signature with favorable prognostic performance, as supported by nomogram-based assessment. Gene Set Enrichment Analysis indicated that cytokine-related processes may participate in CRC progression. TNS1 showed the strongest positive association with natural killer cells (cor = 0.784, P < 0.05) and the strongest inverse association with type 17 T helper cells (cor = -0.279, P < 0.05). Database-based screening predicted 113 candidate compounds targeting CRC. Single-cell analysis further highlighted smooth muscle cells, epithelial cells, endothelial cells, T cells, and B cells as major cellular populations of interest. SPARCL1, MGP, PRELP, and PALMD increased during both early and late B cell maturation, whereas TNS1 and ARHGEF25 were highly expressed across broader cellular contexts. In conclusion, SPARCL1, MGP, PRELP, PALMD, TNS1, ARHGEF25, and PTGIS may represent MRM score-associated prognostic markers in CRC and require further study. - Source: PubMed
Publication date: 2026/08/11
Yue QingfangWen HongxiaZhang ZeyuLi YazhouZhang JinShan LiangLiu DongDuan Xianglong - Extensive experiments document that SPARCL1, a secreted protein that is produced primarily by astrocytes in brain and endothelia throughout the body and that is also known as Hevin, enhances synapse formation. However, the mode of action of SPARCL1 at synapses remains unclear owing to divergent results in the literature. Here, we use cultured neurons from newborn male and female mouse embryos to show that the C-terminal follistatin-like and Ca-binding domains of SPARCL1, which account for only 35% of the total SPARCL1 sequence, are sufficient to potently enhance synapse numbers. SPARCL1 acts at nanomolar concentrations at which SPARCL1 does not robustly bind to neurexins, neuroligins or neurexin/neuroligin complexes but avidly interacts with all teneurins. Strikingly, the follistatin-like domain of SPARCL1 on its own strongly binds to teneurins but is unable to stimulate synapse formation. Only when combined with the SPARCL1 Ca-binding domain does the follistatin-like domain induce synapses, suggesting that SPARCL1 enhances synapse numbers by binding to teneurins via its C-terminal follistatin-like domain and by activating synapse formation via its Ca-binding domain. - Source: PubMed
Publication date: 2026/07/15
Zhang XuchenChen XudongMiao YiSüdhof Thomas C - Glioma-Related Epilepsy (GRE) is a hallmark comorbidity of Low-Grade Glioma (LGG), yet the cellular and molecular mechanisms through which germline epilepsy susceptibility converges with tumor biology to shape clinical outcomes remain poorly understood. - Source: PubMed
Publication date: 2026/07/08
Feng XianglingZhou JiahaoHe ZhenYing XiaominKan Tongtong - Bone fractures in Thoroughbred racehorses are a major welfare problem. Genetic factors contribute to fracture risk. Cell models have previously identified 112 differentially expressed genes in bone-forming osteoblasts derived from horses at high and low genetic risk of fracture. However, 42 of these genes have no published role in bone. In this study, we identified novel roles for a subset of these genes in bone formation. Twenty-six of the 42 genes were expressed in Saos2 cells during basal culture and/or after 21 days of osteogenic culture. Five of these genes (ADSSL1, CABP1, ENO2, SPARCL1 and UCP2) were then stably overexpressed and knocked down, and their effect on osteogenesis was measured. Gene overexpression resulted in significant decreases in Saos2 cell viability and decreased expression of osteogenic genes under basal cell culture, but after 21 days of osteogenic culture there were few significant changes in osteogenic gene expression, collagen deposition or matrix mineralisation. Knockdown of SPARCL1 resulted in total cell death, whereas knockdown of ADSSL1, CABP1, ENO2 and UCP2 resulted in decreased cell viability but limited significant changes in osteogenic gene expression under basal cell culture. However, following osteogenic culture, gene knockdown induced widespread changes in osteogenic gene expression, decreased collagen deposition and increased matrix mineralisation. ADSSL1, CABP1, ENO2 and UCP2 were all expressed at significantly lower levels in osteoblasts from genetically high-risk horses. Taken together, this work demonstrates novel roles for fracture-associated genes in bone formation and matrix mineralisation suggesting these processes may be altered in genetically susceptible horses. - Source: PubMed
Ross Amy CLumsden Ellison SFlood CarolineDudhia JayeshPsifidi AndronikiGuest Deborah J - Vascular dementia (VaD) is a prevalent age-related neurocognitive disorder characterized by progressive cognitive impairment and a lack of disease-modifying therapies. Although age-related brain endothelial dysfunction has been implicated as a central contributor to the pathogenesis of VaD, the molecular mechanisms underlying this process remain incompletely elucidated. - Source: PubMed
Publication date: 2026/06/29
Jin JianchengXu QiuhanPeng GuotaoZhou JiankuaiLiu YuchunMo Jun